Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s stock price traded up 8.8% on Wednesday . The stock traded as high as C$9.27 and last traded at C$9.25. Approximately 404 shares were traded during mid-day trading, a decline of 66% from the average daily volume of 1,197 shares. The stock had previously closed at C$8.50.
Devonian Health Group Stock Up 8.8%
The company has a debt-to-equity ratio of 16.36, a current ratio of 1.07 and a quick ratio of 7.82. The company has a market cap of C$25.72 million, a PE ratio of -4.11 and a beta of 0.44. The business’s 50 day moving average is C$9.45 and its 200-day moving average is C$10.95.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
Featured Stories
- Five stocks we like better than Devonian Health Group
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
